Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
DBH CRISPR/Cas9 KO Plasmid (h): sc-402441
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- DBH CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the DBH genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: DBH Antibody (A-9): sc-365710
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DBH CRISPR/Cas9 KO Plasmid (h) | sc-402441 | 20 µg | $397.00 |
Overview
Dopamine beta-hydroxylase (DBH) encodes a copper-dependent monooxygenase that catalyzes the conversion of dopamine to norepinephrine within secretory vesicles of sympathetic neurons and adrenal chromaffin cells. By controlling catecholamine biosynthesis, DBH influences adrenergic signaling, neuroendocrine stress responses, and downstream GPCR-mediated pathways that regulate cardiovascular tone and central nervous system arousal. Variation in DBH expression or enzymatic activity has been associated with altered norepinephrine homeostasis and has been studied in the context of neuropsychiatric phenotypes and autonomic dysfunction. DBH is therefore a useful target for dissecting catecholamine pathway flux, stimulus-secretion coupling, and neurotransmitter balance in human cellular models.
DBH CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the DBH gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the DBH together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the DBH open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish DBH protein expression.
This CRISPR knockout system enables efficient generation of DBH-deficient cell models for investigation of DBH signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting DBH exon(s) critical for DBH function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple DBH genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by DBH CRISPR/Cas9 KO Plasmid (h) and DBH CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the DBH locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by DBH HDR Plasmid (h) and DBH HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by DBH homology arms to support homology-directed repair at defined DBH target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.